Posted by Michael Wonder on 17 Feb 2021
Lupin responds to NICE Appraisal Consultation Document on NaMuscla (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders
16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) for routine funding to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders in England and Wales.
The Scottish Medicine’s Consortium approved the funding of Namuscla in December 2020 through its orphan drug PACE process. Lupin believes patients living with symptomatic non-dystrophic myotonic disorders have the right to licensed treatment choices that improve their lives.
